Sign in to view content

Modifier-25 Examinations Reduce Travel Burden, Decrease Treatment Cost, and Improve QALY for Exudative Age-Related Macular Degeneration Patients

Henry A Leder, MD

Video
Published 2020

Related

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Annual Meeting Talks
2020
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020

Category: Socioeconomics

See more